Eli Lilly reported that its experimental combination of amylin drug eloraTZP with Zepbound (tirzepatide) achieved up to 23% weight loss in patients with type 2 diabetes and obesity, outperforming Zepbound alone and representing the highest weight loss seen in similar studies to date.
Roche's experimental obesity shot enicepatide reduced blood sugar and body weight by 15.5% in type-2 diabetes patients in a mid-stage trial, with a meaningful proportion reaching normalized glucose levels within less than a year of treatment.
Roche acquired rights to Hanmi Pharmaceutical's obesity drug for $190 million upfront and up to $2.3 billion total. The drug is designed to activate receptors in skeletal muscle to increase muscle mass while reducing fat, addressing a key concern with current GLP-1 weight loss medications.
Amylyx Pharmaceuticals' experimental drug avexitide met its primary endpoint in a Phase 3 trial for post-bariatric hypoglycemia, showing a 55% reduction in serious low blood sugar events compared to placebo in patients who experienced dangerously low blood sugar following weight-loss surgery.
Researchers are developing artificial intelligence tools to detect fatty liver disease early, as the condition affects over a billion people worldwide and is increasingly appearing in young adults, particularly in countries like India where metabolic diseases are rising among people in their 20s.
New research reveals that polyethylene, one of the world's most widely used plastics found in food packaging, may increase the risk of fatty liver disease by disrupting the liver's natural repair mechanisms. The finding is surprising because polyethylene has long been considered biologically inert.
Stanford Medicine scientists have identified a naturally occurring peptide called BRP that suppresses appetite and reduces body weight in animal studies, potentially offering similar benefits to drugs like Ozempic and Wegovy but without side effects such as nausea, digestive issues, and muscle loss. The molecule was discovered using artificial intelligence algorithms.
A major study published in The Lancet analyzing 2.5 million U.S. women found that those with polyendocrine metabolic ovarian syndrome (PMOS, formerly PCOS) have four times the risk of cardiovascular disease, including heart attacks and strokes, compared to women without the condition.
India's drug regulator approved Novo Nordisk's obesity drug Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease, expanding the drug's approved uses beyond weight loss.
Researchers found that semaglutide, the active ingredient in Ozempic and Wegovy, slowed biological aging markers in adults with HIV, marking the first clinical evidence that the drug may influence human aging beyond its metabolic effects.
Eli Lilly announced positive results from its Phase 3 TRIUMPH-1 trial showing retatrutide, an experimental triple-agonist obesity drug, achieved average weight loss of 28.3% at 80 weeks and 30.3% at 104 weeks on the highest dose, matching weight reduction levels typically seen with bariatric surgery.
After more than a decade of discussion, polycystic ovary syndrome (PCOS) has been officially renamed polyendocrine metabolic ovarian syndrome (PMOS) through a global consensus process involving patients and clinicians. The change affects a condition impacting approximately 170 million women worldwide and is expected to improve diagnosis and treatment.
A global consortium of healthcare experts has officially renamed Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS), a change affecting over 170 million women worldwide. Health experts say the new name better reflects the condition's systemic nature and is expected to improve diagnosis and treatment.
A randomized clinical trial found that a vegan diet produced better outcomes than a Mediterranean diet for both metabolic health markers and environmental emissions, providing clear evidence linking dietary choices to human and planetary health.
Mayo Clinic study finds metabolic and bariatric surgery provides significantly greater long-term cardiovascular risk reduction compared to GLP-1 medications in people with obesity, despite both treatments improving heart health.
Researchers who developed GLP-1 obesity medications are now advancing a provocative hypothesis that targeting the GLP-1 hormone may not be necessary for effective weight loss, potentially reshaping the approach to obesity treatment.
New research reveals that approximately 10% of people carry specific genetic variants that make popular diabetes and weight-loss drugs like Ozempic and Wegovy significantly less effective, providing the first genetic explanation for variable drug response.
